Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- Miles, D.W.
- De Haas, S.L.
- Dirix, L.Y.
- Romieu, G.
- Chan, A.
- Pivot, X.
- Tomczak, P.
- Provencher, L.
- Cortés, J.
- Delmar, P.R.
- Scherer, S.J.
ISSN: 0007-0920, 1532-1827
Year of publication: 2013
Volume: 108
Issue: 5
Pages: 1052-1060
Type: Article